‹ Knowledge base
Browse the corpus
Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.
1 passage
abstractpubmed· Abstract 2016· item PMID:26813214
Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis. CLINICAL QUESTION: What immunotherapies for multiple sclerosis are associated with the greatest benefit and highest risk of discontinuation due to adverse events in patients with relapsing-remitting multiple sclerosis? BOTTOM LINE: Alemtuzumab, natalizumab, and fingolimod were associated with the greatest benefit with regard to relapse prevention. Their association with prevention of disability worsening was unclear. Fingolimod was associated with a high risk of treatment discontinuation due to adverse events.